Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobelin for moderate to severe ARDS
ChiCTR2100047403Phase 4Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lobeline in acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Ventilation-free days. Started Jan 2018; status: recruiting.
02
Drugs
lobeline
03
Conditions
acute respiratory distress syndrome (ARDS)acute lung injury (ALI)
Beyond the preview
Go deeper on ChiCTR2100047403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047403.